[{"data":1,"prerenderedAt":29},["ShallowReactive",2],{"$fRW6VNpRGwS4egC4yd7QEnMjWIxhhmlWxwW5CIKpd9ps":3},{"code":4,"show":5,"msg":6,"data":7,"status":28},1,0,"",{"info":8,"next":16,"prev":20,"others":25},{"cate_name":9,"id":4,"cid":10,"title":11,"desc":12,"image":13,"content":14,"is_show":4,"home_recommend":4,"publish_at":15},"好物",3,"SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","SciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and HanKang Capital, with participation from Elik","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153610f29df5455.jpg","\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by B\u003C/span>ioTrack\u003Cspan style=\"font-family: Arial;\"> Capital and Han\u003C/span>Kang\u003Cspan style=\"font-family: Arial;\"> Capital, with participation from \u003C/span>Elikon Venture\u003Cspan style=\"font-family: Arial;\"> and LongRiver Investment\u003C/span>s\u003Cspan style=\"font-family: Arial;\">. The proceeds will mainly be used for preclinical and early clinical development of the company’s existing pipeline.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch is a research-driven biotechnology company focused on iterative innovation of small-molecule oncology drugs. The company explores clinically validated targets from a new perspective, conducts forward-looking differentiated product design, and builds a globally competitive product pipeline.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">The company was co-founded by Dr. Hu Tao, a seasoned serial entrepreneur, and Dr. Zhang Yang, a medicinal chemistry expert. With more than 20 years of professional experience at renowned global and domestic pharmaceutical companies including Merck, Amgen, and WuXi AppTec, Dr. Hu Tao has built multi-dimensional expertise in innovative drug R&D, business development, and corporate governance. Prior to founding SciBrunch, Dr. Hu served as Co-Founder and CEO of Usynova, a biotech company, and successfully led the global exclusive licensing of the preclinical oncology program UA022 to AstraZeneca in 2023.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">Dr. Zhang Yang has nearly 20 years of experience in small-molecule innovative drug R&D and previously served as Vice President of the Domestic Drug Discovery Services Division at WuXi AppTec. Nearly 20 small-molecule oncology innovative drugs designed under his leadership are in various stages of clinical development, and multiple drug candidates have been licensed to overseas pharmaceutical and biotechnology companies.\u003C/span>\u003C/p>",1775712312,{"publish_time":17,"id":10,"title":18,"publish_at":19},"2026-04-09","First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020",1775712313,{"publish_time":21,"id":22,"title":23,"publish_at":24},"2026-04-14",4,"SciBrunch Therapeutics Completes Over  35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent Rounds",1776149657,[26,27],{"publish_time":21,"id":22,"title":23,"publish_at":24},{"publish_time":17,"id":10,"title":18,"publish_at":19},200,1776763000811]